KVAC
Keen Vision Acquisition Corp
$
11.640
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
11.640
Open
11.900
VWAP
11.64
Vol
--
Mkt Cap
107.54M
Low
11.640
Amount
--
EV/EBITDA(TTM)
--
Total Shares
19.37M
EV
108.04M
EV/OCF(TTM)
--
P/S(TTM)
--
Keen Vision Acquisition Corporation is a blank check company. The Company is formed for the purpose of acquiring, engaging in a share exchange, share reconstruction and amalgamation, purchasing all or substantially all the assets of, entering into contractual arrangements, or engaging in any other similar business combination with one or more businesses. The Company is an early-stage company and an emerging growth company. The Company has neither engaged in any operations nor generated any revenues.
Show More
Valuation Metrics
The current forward P/E ratio for Keen Vision Acquisition Corp (KVAC.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Keen Vision Acquisition Corp 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financials
Annual
Quarterly
FY2025Q2
YoY :
-28.17%
-192.04K
Operating Profit
FY2025Q2
YoY :
-68.55%
558.06K
Net Income after Tax
FY2025Q2
YoY :
-44.44%
0.05
EPS - Diluted
FY2025Q2
-178.65K
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
455.2K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
KVAC News & Events
Events Timeline
2025-07-15 (ET)
2025-07-15
08:04:56
Medera, University of Kansas report first patient treated in gene therapy trial
2025-06-24 (ET)
2025-06-24
08:10:28
Medera, Novoheart announce collaboration with scientists at University of CA
2025-06-13 (ET)
2025-06-13
08:06:33
Medera, Novoheart present breakthroughs in human mini-heart platforms, therapy
Sign Up For More Events
Sign Up For More Events
News
7.5
06-24GlobenewswireMedera’s Novoheart Enters New Collaboration to Develop Human Mini-Heart Models Aimed at Transforming Treatment for Hypoplastic Left Heart Syndrome
9.0
06-13GlobenewswireMedera and Novoheart Presented Breakthroughs in Human mini-Heart Platforms and Gene Therapy at ISSCR 2025
9.0
05-19NewsfilterMedera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress
Sign Up For More News
People Also Watch
LRMR
Larimar Therapeutics Inc
3.870
USD
+4.03%
MRT
Marti Technologies Inc
2.490
USD
+0.40%
UTMD
Utah Medical Products Inc
60.740
USD
+0.66%
FDMT
4D Molecular Therapeutics Inc
6.530
USD
-3.12%
LFMD
LifeMD Inc
6.500
USD
+5.01%
FUNC
First United Corp
37.230
USD
+1.94%
AOUT
American Outdoor Brands Inc
10.350
USD
+0.10%
ACB
Aurora Cannabis Inc
5.300
USD
+1.34%
EVC
Entravision Communications Corp
2.430
USD
-2.02%
LCNB
LCNB Corp
15.950
USD
-0.50%
FAQ
What is Keen Vision Acquisition Corp (KVAC) stock price today?
The current price of KVAC is 11.64 USD — it has decreased -0.43 % in the last trading day.
What is Keen Vision Acquisition Corp (KVAC)'s business?
What is the price predicton of KVAC Stock?
What is Keen Vision Acquisition Corp (KVAC)'s revenue for the last quarter?
What is Keen Vision Acquisition Corp (KVAC)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Keen Vision Acquisition Corp (KVAC)'s fundamentals?
How many employees does Keen Vision Acquisition Corp (KVAC). have?